Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific ( (BSX) ) just unveiled an announcement.
Boston Scientific Corporation has announced the resumption of its AVANT GUARD clinical trial, focusing on drug-naïve patients with persistent atrial fibrillation. This decision follows a thorough assessment and collaboration with the study’s data monitoring committee, signaling potential advancements in treatment options for this patient group.
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.